Copy
April, 09 2019
Giving healthcare companies the exposure they deserve. Every Tuesday.
Share
Tweet
Share
Forward

FEATURED STORY

BioSig unlocking future of bioelectronic medicine through signal processing

With the FDA’s 510(k) clearance of its PURE EP System in August 2018 and first successful patient cases, BioSig (NASDAQ:BSGM) is advancing its vision to improve medicine through biomedical signal processing.

“Our larger focus is on bioelectronic medicine, a new field of healthcare, which uses biomedical signals to develop new tools to help treat challenging diseases, such as heart conditions, hypertension, diabetes and chronic pain,” Kenneth Londoner, founder, chairman and CEO, says in an interview with BioTuesdays.

BioSig’s first product, PURE EP System, has been designed to provide enhanced cardiac signals during the procedures used to treat abnormal heart rates and rhythms.

“PURE EP aims to minimize the effect noise and other electrical interference in the electrophysiology (EP) lab has on cardiac procedures. The system creates high-fidelity cardiac signals, which may provide better data to a physician, potentially improving the accuracy and efficacy of catheter ablation procedures used to treat arrhythmia, atrial fibrillation and ventricular tachycardia,” he adds.
 
Read the Story

SELECT BRIEFS

(TSX:PRN; OTCQX:PRFMF)

Profound Medical

Posts positive top line pivotal trial results in prostate cancer with TULSA-PRO.
 

(OTCQX:IGXT;TSXV:IGX)

IntelGenx

Among few Quebec companies leading cannabis edibles market.

 

(TSX-V:BCT) (OTCQB:BCTXF)

BriaCell Therapeutics

Immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial.
 

(NASDAQ:FIXX)

Homology Medicines

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy.

 

More Briefs


Wall Street News


About BioTuesdays

 
BioTuesdays was created in 2009 by Kilmer Lucas, a leading healthcare-only investor relations firm. Employing a unique "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized IR & PR programs for its drug development, medical device, cell therapy, diagnostics and healthcare services clients. But, most of BioTuesdays' content isn't client-driven. Rather, our mission is to give as many great healthcare companies and their stories as much exposure as we can.
Want to be featured in BioTuesdays? Get in touch with us.
Copyright © 2019 Kilmer Lucas, All rights reserved.
You are receiving this email because you signed up for the BioTuesdays newsletter.
Privacy Policy

BioTuesdays
PO Box 297
Carlisle, ON L0R 1H0 

subscribe | unsubscribe | update your preferences